<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biofrontera Inc — News on 6ix</title>
<link>https://6ix.com/company/biofrontera-inc</link>
<description>Latest news and press releases for Biofrontera Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 19 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biofrontera-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354c5778dffbe2df0e579b.webp</url>
<title>Biofrontera Inc</title>
<link>https://6ix.com/company/biofrontera-inc</link>
</image>
<item>
<title>Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-reports-record-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-reports-record-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the</description>
</item>
<item>
<title>Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-reports-positive-phase-2b-results-supporting-further-development-of-ameluzr-photodynamic-therapy-for-moderate-to-severe-acne-vulgaris-1</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-reports-positive-phase-2b-results-supporting-further-development-of-ameluzr-photodynamic-therapy-for-moderate-to-severe-acne-vulgaris-1</guid>
<pubDate>Mon, 09 Mar 2026 13:15:00 GMT</pubDate>
<description>• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz® PDT versus vehicle • 3-hour incubation regimen identified as the most promising protocol for further clinical development • Acne vulgaris represents a promising potential future indication for Ameluz®, significantly broadening the Company’s dermatology pipeline WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company spe</description>
</item>
<item>
<title>Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris </title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-reports-positive-phase-2b-results-supporting-further-development-of-ameluzr-photodynamic-therapy-for-moderate-to-severe-acne-vulgaris</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-reports-positive-phase-2b-results-supporting-further-development-of-ameluzr-photodynamic-therapy-for-moderate-to-severe-acne-vulgaris</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz® PDT versus vehicle • 3-hour incubation regimen identified as the</description>
</item>
<item>
<title>U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable</title>
<link>https://6ix.com/company/biofrontera-inc/news/us-patent-office-issues-final-written-decision-finding-all-challenged-claims-of-sun-pharmas-patent-11697028-to-be-unpatentable</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/us-patent-office-issues-final-written-decision-finding-all-challenged-claims-of-sun-pharmas-patent-11697028-to-be-unpatentable</guid>
<pubDate>Thu, 26 Feb 2026 14:15:00 GMT</pubDate>
<description>WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board (the “Board”) issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries, Inc.’s U.S. Patent No. 11,697,028 (the “’028 Patent”) to be unpatentable. As previously disclosed in Biofronter</description>
</item>
<item>
<title>Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-announces-database-lock-141500699</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-announces-database-lock-141500699</guid>
<pubDate>Tue, 17 Feb 2026 14:15:00 GMT</pubDate>
<description>Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansionData to complement previously announced positive Phase 3 efficacy results on extremities, neck and trunkSupplemental NDA submission for extremities, neck and trunk indication expected in Q3 2026 WOBURN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photo</description>
</item>
<item>
<title>Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-announces-fda-filing-acceptance-141500110</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-announces-fda-filing-acceptance-141500110</guid>
<pubDate>Wed, 11 Feb 2026 14:15:00 GMT</pubDate>
<description>Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal Cell Carcinoma (sBCC) in the USBCC is the most common skin cancer in the US with 3.6 million cases diagnosed annually1 WOBURN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercializatio</description>
</item>
<item>
<title>Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-announces-positive-results-phase-141500130</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-announces-positive-results-phase-141500130</guid>
<pubDate>Mon, 09 Feb 2026 14:15:00 GMT</pubDate>
<description>Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz® vs. vehicle gel (p<0.0003)Actinic keratosis (AK) is the most common skin condition diagnosed by US dermatologists1If left untreated, AK may progress to squamous cell carcinoma2,3 WOBURN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic</description>
</item>
<item>
<title>Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-announces-record-preliminary-133000364</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-announces-record-preliminary-133000364</guid>
<pubDate>Tue, 13 Jan 2026 13:30:00 GMT</pubDate>
<description>Fourth quarter results represent highest quarterly revenue in Company’s historyQ4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz®Full year 2025 revenues also expected to show double-digit growth of 11% to 13% WOBURN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for the fourth quarter</description>
</item>
<item>
<title>Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-announces-data-locks-134500469</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-announces-data-locks-134500469</guid>
<pubDate>Thu, 08 Jan 2026 13:45:00 GMT</pubDate>
<description>Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026Data generated will support key regulatory milestones for Ameluz PDT in both indicationsAK and acne are the two most commonly diagnosed skin disorders in the US1 WOBURN, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announ</description>
</item>
<item>
<title>Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-completes-transfer-ameluz-134500817</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-completes-transfer-ameluz-134500817</guid>
<pubDate>Thu, 18 Dec 2025 13:45:00 GMT</pubDate>
<description>• Ameluz® and RhodoLED® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc.• Assignment to Biofrontera Inc. of 11 granted US patents, 10 pending US patent applications and various trademarks associated with Ameluz® and the RhodoLED® Lamp Series has been applied for registration with the relevant authorities, including the US Patent Office (USPTO)• In addition, 19 international patent applications and/or registered desig</description>
</item>
<item>
<title>Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities</title>
<link>https://6ix.com/company/biofrontera-inc/news/last-patient-completes-biofrontera-phase-140000398</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/last-patient-completes-biofrontera-phase-140000398</guid>
<pubDate>Thu, 04 Dec 2025 14:00:00 GMT</pubDate>
<description>Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz® over treatment area of 240 cm2Completion of this study marks a key milestone towards a planned summer 2026 FDA submission for FDA approval for the use of Ameluz® on all non-face and scalp areas WOBURN, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercial</description>
</item>
<item>
<title>Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-announces-filing-supplemental-134500641</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-announces-filing-supplemental-134500641</guid>
<pubDate>Tue, 02 Dec 2025 13:45:00 GMT</pubDate>
<description>sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to FDAPrimary and key secondary endpoints met with high statistical significance (p <0.0001)Favorable recurrence outcomes at one-year follow-upBCC is the most common skin cancer in the US with more than 3 million cases diagnosed annually1 WOBURN, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (</description>
</item>
<item>
<title>Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-reports-third-quarter-131500743</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-reports-third-quarter-131500743</guid>
<pubDate>Thu, 13 Nov 2025 13:15:00 GMT</pubDate>
<description>Conference call will be held today, Thursday, November 13 at 10:00 am ET Woburn, MA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and nine months ended September 30, 2025 and provided a business update. Financial highlights Revenues for the first nine months of 2025 were stable with $24.</description>
</item>
<item>
<title>Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-announces-sale-license-130000530</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-announces-sale-license-130000530</guid>
<pubDate>Fri, 07 Nov 2025 13:00:00 GMT</pubDate>
<description>Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash position, which is expected to fund Biofrontera to profitability.Proceeds will support the growth of Biofrontera’s commercial photodynamic therapy (PDT) platform, and expansion of Ameluz® into additional indications. WOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (</description>
</item>
<item>
<title>Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-report-third-quarter-210100923</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-report-third-quarter-210100923</guid>
<pubDate>Thu, 06 Nov 2025 21:01:00 GMT</pubDate>
<description>WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, November 12, 2025. The company will host a conference call on Thursday, November 13 at 10:00am Eastern Time to discuss those results,</description>
</item>
<item>
<title>Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-closes-purchase-ameluz-124500661</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-closes-purchase-ameluz-124500661</guid>
<pubDate>Thu, 23 Oct 2025 12:45:00 GMT</pubDate>
<description>Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent Biofrontera AG.New earnout structure reduces payment rate to 12%–15% of U.S. net sales from 25%–35%.Closing releases final $2.5 million of $11 million financing led by existing investors Rosalind Advisors and AIGH Capital Management, which is expected to fund Biofrontera Inc. to profitability. WOBURN, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Biofrontera I</description>
</item>
<item>
<title>Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-participate-lytham-partners-131500994</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-participate-lytham-partners-131500994</guid>
<pubDate>Fri, 26 Sep 2025 13:15:00 GMT</pubDate>
<description>Woburn, MA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 1:15 p.m. ET</description>
</item>
<item>
<title>Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-engages-lytham-partners-132000483</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-engages-lytham-partners-132000483</guid>
<pubDate>Tue, 23 Sep 2025 13:20:00 GMT</pubDate>
<description>WOBURN, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), has engaged Lytham Partners to lead a strategic investor relations and shareholder communication program. For more than 20 years, Lytham Partners has been one of the country's leading investor relations firms, having created one of the industry's largest and most diverse</description>
</item>
<item>
<title>Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-announces-last-patient-143000787</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-announces-last-patient-143000787</guid>
<pubDate>Tue, 16 Sep 2025 14:30:00 GMT</pubDate>
<description>All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in October 2024 for use of up to 3 tubes of Ameluz® per treatmentStudy results expected to form the basis of a supplemental New Drug Application (sNDA) planned for submission in Q2 2026 WOBURN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercial</description>
</item>
<item>
<title>Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris</title>
<link>https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-announces-last-patient-122500296</link>
<guid isPermaLink="true">https://6ix.com/company/biofrontera-inc/news/biofrontera-inc-announces-last-patient-122500296</guid>
<pubDate>Mon, 25 Aug 2025 12:25:00 GMT</pubDate>
<description>Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansionMore than 50 million people affected by acne in US each year, with market valued at $5.7 billion in 2024 WOBURN, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of phot</description>
</item>
</channel>
</rss>